TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23019380

Group type: EXPERIMENTAL
Intervention: Conditioning paradigm using clearly visible cues for high and low pain
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Conditioned placebo and nocebo responses triggered by nonconscious (masked) exposures to the same cues
Number of subjects: 40
Study: 19200370

Group type: EXPERIMENTAL
Intervention: Quetiapine monotherapy
Number of subjects: 21
Study: 17335405

Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix (ADM) with enamel matrix derivative (EMD)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Acellular dermal matrix (ADM) alone
Number of subjects: 14
Study: 14697471

Group type: EXPERIMENTAL
Intervention: Conduction disorders (CDs) present during admission
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complete atrioventricular block
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Right bundle branch block
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients without conduction disorders (CDs)
Number of subjects: 0
Study: 11567913

Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Number of subjects: 0
Study: 9543613

Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg b.d. for 7 days starting 5 days before chemotherapy)
Number of subjects: 8
Study: 7932825

Group type: EXPERIMENTAL
Intervention: Chronomodulated drug delivery (schedule B)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Constant-rate drug delivery (schedule A)
Number of subjects: 92
Study: 3284943

Group type: EXPERIMENTAL
Intervention: Intravenous APSAC (30 U in 2 to 4 min)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Intracoronary streptokinase (160,000 U over 60 min)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Intravenous APSAC
Number of subjects: 240

Group type: COMPARATOR
Intervention: Intracoronary streptokinase
Number of subjects: 240
Study: 29446098

Group type: EXPERIMENTAL
Intervention: VDZ-aTNF (Vedolizumab with anti-TNF co-exposure)
Number of subjects: 75

Group type: COMPARATOR
Intervention: VDZ (Vedolizumab without anti-TNF co-exposure)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: VDZ-aTNF
Number of subjects: 75

Group type: COMPARATOR
Intervention: VDZ
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Corticosteroid-free remission
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Corticosteroid-free response
Number of subjects: 75

Group type: COMPARATOR
Intervention: VDZ-aTNF and VDZ
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Infliximab (separate cohort)
Number of subjects: 75
Study: 27603509

Group type: EXPERIMENTAL
Intervention: Simplified modified Atkins diet
Number of subjects: 81

Group type: COMPARATOR
Intervention: No dietary intervention (Control)
Number of subjects: 81
Study: 24750013

Group type: EXPERIMENTAL
Intervention: Surgery with cardiopulmonary bypass
Number of subjects: 60

Group type: COMPARATOR
Intervention: Surgery without cardiopulmonary bypass
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass
Number of subjects: 60
Study: 22519866

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (50 mg.kg(‐1) followed by continuous infusion of 15 mg.kg(‐1).h(‐1))
Number of subjects: 40

Group type: COMPARATOR
Intervention: Isotonic saline (same volume as magnesium group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Number of subjects: 40
Study: 20497133

Group type: EXPERIMENTAL
Intervention: Low-exposure ethanol (targeted breathalyzer = 0.040 g/dl)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: High-exposure ethanol (targeted breathalyzer = 0.100 g/dl)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 48
Study: 18375328

Group type: EXPERIMENTAL
Intervention: Continuous extrapleural infusion of ropivacaine 0.2% at a rate of 6 mL/h
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Continuous extrapleural infusion of ropivacaine 0.2% at a rate of 9 mL/h
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Comparison of the two dosing regimens (6 mL/h vs 9 mL/h)
Number of subjects: 17
Study: 16161996

Group type: EXPERIMENTAL
Intervention: Intravenous application of compound 19 (BIBN4096)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CGRP receptor antagonists (compound 19)
Number of subjects: 0
Study: 12418600

Group type: EXPERIMENTAL
Intervention: Chlorhexidine varnish (40%) application
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo varnish
Number of subjects: 40
Study: 10353516

Group type: EXPERIMENTAL
Intervention: Daily dapsone (2 mg/kg)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Daily dapsone (1 mg/kg)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Weekly dapsone (4 mg/kg)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Daily dapsone (1 mg/kg) and Daily dapsone (2 mg/kg)
Number of subjects: 94
Study: 8600628

Group type: EXPERIMENTAL
Intervention: TNFR:Fc
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control
Number of subjects: 12
Study: 8440768

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg/day tirilazad mesylate
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg/day tirilazad mesylate
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 2.0 mg/kg/day tirilazad mesylate
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 4.0 mg/kg/day tirilazad mesylate
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 6.0 mg/kg/day tirilazad mesylate
Number of subjects: 50

Group type: COMPARATOR
Intervention: Citrate vehicle placebo
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravenous normal saline placebo
Number of subjects: 50
Study: 3092653

Group type: EXPERIMENTAL
Intervention: Enprostil (35 micrograms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enprostil (dose not specified)
Number of subjects: 0
Study: 29927930

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 3879

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3879
Study: 27714459

Group type: EXPERIMENTAL
Intervention: Arthrocentesis + Sodium hyaluronate (SH) injection
Number of subjects: 30

Group type: COMPARATOR
Intervention: Arthrocentesis only
Number of subjects: 30
Study: 25635327

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Platelet activation
Number of subjects: 0
Study: 22729967

Group type: EXPERIMENTAL
Intervention: DPA supplementation (8 g of pure DPA)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: EPA supplementation (8 g of pure EPA)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo treatment (olive oil)
Number of subjects: 10
Study: 21708185

Group type: EXPERIMENTAL
Intervention: Minimum 20 minutes of daily commuter cycling during 8 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: No change in lifestyle (control group)
Number of subjects: 48
Study: 17869446

Group type: COMPARATOR
Intervention: 5-fluorouracil (FU) plus leucovorin (LV) (FU+LV)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: oral uracil and tegafur (UFT) plus LV (UFT+LV)
Number of subjects: 155
Study: 16424784

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 250

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 250
Study: 14521531

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (20 mg per day for 10 days)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo (750 mg glucose per day for 10 days)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study: 10856481

Group type: EXPERIMENTAL
Intervention: 75 IU subcutaneous (s.c.) recombinant FSH
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 150 IU subcutaneous (s.c.) recombinant FSH
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 225 IU subcutaneous (s.c.) recombinant FSH
Number of subjects: 46

Group type: COMPARATOR
Intervention: 150 IU intramuscular (i.m.) recombinant FSH
Number of subjects: 46
Study: 7733035

Group type: EXPERIMENTAL
Intervention: Low-molybdenum diet (22 micrograms/d) for 102 days
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Molybdenum-supplemented diet (467 micrograms/d) for 18 days
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Low dietary molybdenum intake
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: High dietary molybdenum intake
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Estimation of minimum dietary molybdenum requirement
Number of subjects: 4
Study: 2103967

Group type: EXPERIMENTAL
Intervention: Beta-cyclodextrin-piroxicam (beta CDP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nabumetone (NAB)
Number of subjects: 40
Study: 7339229

Group type: EXPERIMENTAL
Intervention: 5 days per week training
Number of subjects: 75

Group type: COMPARATOR
Intervention: 4 days per week training
Number of subjects: 75

Group type: COMPARATOR
Intervention: 3 days per week training
Number of subjects: 75

Group type: COMPARATOR
Intervention: 2 days per week training
Number of subjects: 75

Group type: COMPARATOR
Intervention: 1 day per week training
Number of subjects: 75
Study: 30913217

Group type: EXPERIMENTAL
Intervention: Decision aid (DA) with detailed information on benefits and harms of screening
Number of subjects: 400

Group type: COMPARATOR
Intervention: Standard leaflet that did not mention harms
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Decision aid (DA)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Standard leaflet
Number of subjects: 400
Study: 28124534

Group type: COMPARATOR
Intervention: Electrical stimulation with pelvic floor muscle training (ES + PFMT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Percutaneous tibial nerve stimulation (PTNS)
Number of subjects: 60
Study: 25231677

Group type: EXPERIMENTAL
Intervention: Calcium 1,200 mg/day
Number of subjects: 323

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 323
Study: 23652739

Group type: EXPERIMENTAL
Intervention: Herbst multibracket (MB) treatment
Number of subjects: 37
Study: 21612746

Group type: EXPERIMENTAL
Intervention: Roflumilast (500 μg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Warfarin (25 mg) with Roflumilast
Number of subjects: 24

Group type: COMPARATOR
Intervention: Warfarin (25 mg) with Placebo
Number of subjects: 24
Study: 19127171

Group type: EXPERIMENTAL
Intervention: MPH-OROS
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 16433771

Group type: EXPERIMENTAL
Intervention: Everolimus (3 mg/day)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Azathioprine (1-3 mg/kg/day)
Number of subjects: 213
Study: 15541209

Group type: EXPERIMENTAL
Intervention: Trospium chloride 20-mg tablets, administered twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo, administered twice daily
Number of subjects: 0
Study: 11775562

Group type: EXPERIMENTAL
Intervention: 0.6 ml (5700 IU) of nadroparin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1.0 ml (9500 IU) of nadroparin
Number of subjects: 60
Study: 9280815

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (reviparin sodium)
Number of subjects: 1021

Group type: COMPARATOR
Intervention: Unfractionated heparin (adjusted-dose, intravenous)
Number of subjects: 1021
Study: 7839476

Group type: EXPERIMENTAL
Intervention: 2 mg nebulized budesonide
Number of subjects: 37

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 37
Study: 3222154

Group type: EXPERIMENTAL
Intervention: Splenic Irradiation (SI)
Number of subjects: 660

Group type: COMPARATOR
Intervention: Chlorambucil
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Chlorambucil with or without prednisolone
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Splenic Irradiation (SI) vs Chlorambucil with or without prednisolone
Number of subjects: 660
Study: 31698359

Group type: EXPERIMENTAL
Intervention: Subcutaneous AT (SAT) mass, Visceral AT (VAT) mass, and gene expression in SAT
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Subcutaneous AT (SAT) mass
Number of subjects: 156
Study: 28275830

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 180

Group type: COMPARATOR
Intervention: Varenicline vs. Bupropion
Number of subjects: 180
Study: 25401522

Group type: EXPERIMENTAL
Intervention: Biogenetic intervention
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control
Number of subjects: 41
Study: 23631869

Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 418

Group type: COMPARATOR
Intervention: Standard Treatment
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Public Assistance Income
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Illegal Income
Number of subjects: 418
Study: 21399454

Group type: EXPERIMENTAL
Intervention: Mechanical valves (positive-displacement valves)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Split-septum devices
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neutral-, negative-, and positive-displacement types
Number of subjects: 0
Study: 18484151

Group type: EXPERIMENTAL
Intervention: Collagen implant
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional procedure
Number of subjects: 20
Study: 16980862

Group type: EXPERIMENTAL
Intervention: Internal maxillary distractors
Number of subjects: 29

Group type: COMPARATOR
Intervention: Immediate fragment transposition using miniplates and screw fixation (Control)
Number of subjects: 29
Study: 14523272

Group type: EXPERIMENTAL
Intervention: Zidovudine triphosphate above 30 fmol/10(6) cells
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Lamivudine triphosphate above 7017 fmol/10(6) cells
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Zidovudine and lamivudine triphosphate concentrations
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Triphosphate concentrations in women
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: HIV-RNA level under 50 copies/ml
Number of subjects: 33

Group type: COMPARATOR
Intervention: Indinavir concentrations
Number of subjects: 33
Study: 10801756

Group type: EXPERIMENTAL
Intervention: L-arginine (9 g daily for 1 month)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 8739380

Group type: EXPERIMENTAL
Intervention: Mechanical stimulation of the penis using an electromechanical hammer with surface electrodes.
Number of subjects: 21

Group type: COMPARATOR
Intervention: Electrical stimulation of the penis.
Number of subjects: 21
Study: 1425206

Group type: EXPERIMENTAL
Intervention: Levodropropizine (60 mg t.i.d. for 7 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (for 7 days)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Levodropropizine and Placebo
Number of subjects: 20
Study: 4017833

Group type: EXPERIMENTAL
Intervention: Atropine (40 micrograms/kg/4 hr)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cerulein (360 ng/kg/4 hr)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 6
Study: 29891566

Group type: EXPERIMENTAL
Intervention: Mild depressive symptoms in mothers (Patient Health Questionnaire‐9 ≥5)
Number of subjects: 1031

Group type: EXPERIMENTAL
Intervention: Exposure to physical IPV
Number of subjects: 1031

Group type: EXPERIMENTAL
Intervention: Exposure to sexual IPV
Number of subjects: 1031
Study: 26948850

Group type: EXPERIMENTAL
Intervention: Higher third-trimester stress
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Unplanned cesarean delivery
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Vaginal delivery
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Sociodemographic covariates, mode of delivery, and prenatal mood
Number of subjects: 136
Study: 24241212

Group type: EXPERIMENTAL
Intervention: Linifanib at a maximum tolerated dose of 0.25 mg/kg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 24
Study: 23256712

Group type: EXPERIMENTAL
Intervention: Communication training for general practitioners and pediatricians
Number of subjects: 30000

Group type: EXPERIMENTAL
Intervention: Communication training plus point-of-care testing
Number of subjects: 30000

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30000
Study: 21067470

Group type: EXPERIMENTAL
Intervention: 200 μg dexamethasone cipecilate
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 17426473

Group type: EXPERIMENTAL
Intervention: Albendazole for 3 months preoperatively (Group III)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Albendazole for unspecified duration (Group I)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Albendazole for unspecified duration (Group II)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (Group IV)
Number of subjects: 0
Study: 15739076

Group type: COMPARATOR
Intervention: Ginkgo biloba (120 mg, single dose)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Ginkgo biloba (120 mg/day for 6 weeks)
Number of subjects: 92
Study: 12073414

Group type: EXPERIMENTAL
Intervention: Physician reminder (753 patients)
Number of subjects: 2626

Group type: EXPERIMENTAL
Intervention: Patient reminder (phone call, 312 patients)
Number of subjects: 2626

Group type: EXPERIMENTAL
Intervention: Patient reminder (letter, 337 patients)
Number of subjects: 2626

Group type: COMPARATOR
Intervention: Control group (913 patients)
Number of subjects: 2626
Study: 9458201

Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis patients
Number of subjects: 106
Study: 7629414

Group type: EXPERIMENTAL
Intervention: Buffered lidocaine (BL)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Unbuffered lidocaine (L)
Number of subjects: 7
Study: 2611076

Group type: EXPERIMENTAL
Intervention: nalbuphine 0.3 mg kg‐1
Number of subjects: 80

Group type: COMPARATOR
Intervention: morphine 0.15 mg kg‐1
Number of subjects: 80
Study: 1195025

Group type: EXPERIMENTAL
Intervention: Trial group (no knowledge of medical evaluation results)
Number of subjects: 4936

Group type: COMPARATOR
Intervention: Control group (results of medical evaluation fully disclosed)
Number of subjects: 4936

Group type: EXPERIMENTAL
Intervention: Trial group (medical evaluation category A - normal risk)
Number of subjects: 4936

Group type: EXPERIMENTAL
Intervention: Trial group (no preemployment medical evaluation)
Number of subjects: 4936

Group type: EXPERIMENTAL
Intervention: Preemployment health evaluation
Number of subjects: 4936
Study: 30887731

Group type: EXPERIMENTAL
Intervention: 1-L·kg·min-1
Number of subjects: 168

Group type: COMPARATOR
Intervention: 2-L·kg·min-1
Number of subjects: 168
Study: 28034609

Group type: EXPERIMENTAL
Intervention: Respecting the Circle of Life (RCL) intervention
Number of subjects: 267
Study: 25524798

Group type: EXPERIMENTAL
Intervention: Palbociclib plus letrozole
Number of subjects: 165

Group type: COMPARATOR
Intervention: Letrozole alone
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Palbociclib plus letrozole (Cohort 1)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Letrozole alone (Cohort 1)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Palbociclib plus letrozole (Cohort 2)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Letrozole alone (Cohort 2)
Number of subjects: 165
Study: 23645608

Group type: EXPERIMENTAL
Intervention: Pictorial health warnings (PHWs) on cigarette packages
Number of subjects: 500
Study: 21609504

Group type: EXPERIMENTAL
Intervention: Assessment with feedback during individual treatment (using Readiness to Change Questionnaire and Personal Resources Diagnostic System)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Usual treatment without within treatment assessment with feedback
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Assessment with feedback during individual treatment
Number of subjects: 280
Study: 19104843

Group type: EXPERIMENTAL
Intervention: Pain Education Program (PEP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 120
Study: 17764789

Group type: EXPERIMENTAL
Intervention: Transcutaneous immunisation (TCI) with live-attenuated measles vaccine ROUVAX
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subcutaneous route
Number of subjects: 0
Study: 15075414

Group type: EXPERIMENTAL
Intervention: Self-reported medications
Number of subjects: 294

Group type: COMPARATOR
Intervention: Pharmacy records
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Health status
Number of subjects: 294
Study: 11251037

Group type: EXPERIMENTAL
Intervention: Molecular adsorbent recirculating system (MARS) treatment for 6-8 hours
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: MARS treatment
Number of subjects: 400
Study: 9291514

Group type: EXPERIMENTAL
Intervention: Emergency physicians prescribing narcotics (codeine or oxycodone compounds)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Family practice physicians prescribing narcotics
Number of subjects: 165

Group type: COMPARATOR
Intervention: Pediatricians prescribing narcotics
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Overall physician willingness to prescribe stronger medications than acetaminophen or NSAIDs
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Comparison of narcotic prescriptions for 2-year-old vs 22-year-old patients
Number of subjects: 165

Group type: COMPARATOR
Intervention: Comparison of narcotic prescriptions between pediatricians and family practice physicians
Number of subjects: 165
Study: 8184497

Group type: EXPERIMENTAL
Intervention: Intensive dynamic back extension and abdominal exercises without low back pain being the limiting factor
Number of subjects: 96

Group type: COMPARATOR
Intervention: Traditional mild, general mobility-improving exercises within pain limits
Number of subjects: 96

Group type: COMPARATOR
Intervention: Historical control group (not specified intervention)
Number of subjects: 96
Study: 2453700

Group type: EXPERIMENTAL
Intervention: Allapinin (0.39 mg/kg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Allapinin (doses > 0.32 mg/kg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Allapinin (doses > 0.42 mg/kg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Allapinin
Number of subjects: 42
Study: 29599478

Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside (NR) supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27631142

Group type: EXPERIMENTAL
Intervention: Citalopram (20-60 mg/d) for 8-14 weeks
Number of subjects: 3577
Study: 24205974

Group type: EXPERIMENTAL
Intervention: Teneligliptin 20 mg once daily
Number of subjects: 194

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194